Literature DB >> 22430336

Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review.

Borlingegowda Viswanatha1, Dadarao Sumatha, Maliyappanahalli Siddappa Vijayashree.   

Abstract

A comparative clinical study was carried out that included 50 cases of otomycosis in immunocompetent patients and 50 cases of otomycosis in immunocompromised patients. Clinical presentation, predisposing factors, mycologic profile, and treatment outcomes were compared. Aspergillus spp were the most commonly isolated fungi in the immunocompetent group, and Candida albicans in the immunocompromised group. Bilateral involvement was more common in the immunocompromised group. All the patients were treated with topical clotrimazole ear drops. Four patients in the immunocompromised group did not respond to treatment with clotrimazole but were treated successfully with fluconazole ear drops. Three patients had a small tympanic membrane perforation due to otomycosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430336     DOI: 10.1177/014556131209100308

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  10 in total

Review 1.  Otomycosis in iran: a review.

Authors:  Maral Gharaghani; Zahra Seifi; Ali Zarei Mahmoudabadi
Journal:  Mycopathologia       Date:  2015-01-30       Impact factor: 2.574

2.  Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Somayeh Roodgari; Mojtaba Taghizadeh Armaki; Mohammad Taghi Hedayati; Tahereh Shokohi; Iman Haghani; Javad Javidnia; Firoozeh Kermani; Hamid Badali; Mahdi Abastabar
Journal:  Mycopathologia       Date:  2021-03-15       Impact factor: 2.574

Review 3.  Scedosporium apiospermum Otitis Complicated by a Temporomandibular Arthritis: A Case Report and Mini-Review.

Authors:  A Huguenin; V Noel; A Rogez; C Chemla; I Villena; D Toubas
Journal:  Mycopathologia       Date:  2015-06-24       Impact factor: 2.574

Review 4.  Otomycosis in the South of Iran with a High Prevalence of Tympanic Membrane Perforation: A Hospital-Based Study.

Authors:  Javad Javidnia; Zahra Ghotbi; Aynaz Ghojoghi; Kavous Solhjoo; Mohamed Mahdi Alshahni; Seyed Ali Jeddi; Bahram Ahmadi; Sadegh Nouripour-Sisakht; Saham Ansari; Gholamreza Shokoohi
Journal:  Mycopathologia       Date:  2022-03-26       Impact factor: 2.574

5.  Otomycosis in a Rural Community Attending a Tertiary Care Hospital: Assessment of Risk Factors and Identification of Fungal and Bacterial Agents.

Authors:  Priti Agarwal; Leimapokpam Sumitra Devi
Journal:  J Clin Diagn Res       Date:  2017-06-01

6.  Effect of long-term exposure to mobile phone radiation on alpha-Int1 gene sequence of Candida albicans.

Authors:  Ariyo Shahin-Jafari; Mansour Bayat; Mohammad Hassan Shahhosseiny; Parviz Tajik; Shahla Roudbar-Mohammadi
Journal:  Saudi J Biol Sci       Date:  2015-05-09       Impact factor: 4.219

7.  A Comparison of Antifungal Drugs and Traditional Antiseptic Medication for Otomycosis Treatment: A Systematic Review and Meta-Analysis.

Authors:  Shunyu Wu; Yin Cheng; Shunzhang Lin; Huanhai Liu
Journal:  Front Surg       Date:  2021-12-22

8.  Identification of the Fungal Community in Otomycosis by Internal Transcribed Spacer Sequencing.

Authors:  Xiaona Gu; Xiangrong Cheng; Jinhua Zhang; Wandong She
Journal:  Front Microbiol       Date:  2022-03-15       Impact factor: 5.640

9.  Monkey finger mycology? First case of otomycosis externa caused by Trichophyton simii after encounter with a monkey.

Authors:  Sigmund Krajden; Richard C Summerbell; Aswani Datt; Mike Hawke; James Scott
Journal:  Med Mycol Case Rep       Date:  2022-06-09

10.  Primary otomycosis in the Indian subcontinent: predisposing factors, microbiology, and classification.

Authors:  Sampath Chandra Prasad; Subbannayya Kotigadde; Manisha Shekhar; Nikhil Dinaker Thada; Prashanth Prabhu; Tina D' Souza; Kishore Chandra Prasad
Journal:  Int J Microbiol       Date:  2014-05-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.